Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics

ALINA COSTINA LUCA1, INGRITH CRENGUȚA MIRON1, LAURA MIHAELA TRANDAFIR1, ELENA COJOACARU2, IOANA ALEXANDRA PĂDURET1, MIOARA FLORENTINA TRANDAFIRESCU3, ALIN CONSTANTIN IORDACHE4, ELENA ȚARCA5

1Department of Mother and Child Medicine – Pediatrics, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania
2Department of Morphofunctional Sciences I – Pathology, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania
3Department of Morphofunctional Sciences I – Histology, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania
4Second Surgery Department – Neurosurgery, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania
5Second Surgery Department – Pediatric Surgery, Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania

Abstract

Infantile hemangiomas (IHs) are the most frequent pediatric benign vascular tumors, with a reported incidence of 5% to 10%. They have self-limiting evolution pattern divided into a growth phase in the first 12 months and a regression one, that may take up to 10 years. Occasionally, hemangiomas might lead to local or systemic complications, depending on their morphological characteristics. The first line of treatment is β-blockers, such as Propranolol, Timolol, Nadolol, administered either locally or systemically. Newer therapeutic strategies involving laser therapy and angiogenesis-converting enzyme inhibitors are being studied, while older treatment modalities like corticosteroids, Imiquimod, Vincristine, Bleomycin and Interferon-α have become second line therapy options. Before establishing the appropriate treatment, clinical, histological, and imaging investigations are required.

Keywords: infantile hemangioma, histopathology, genetics, management, differential diagnosis.

Introduction

Infantile hemangioma (IH) is the most common vascular tumor of the child, with an incidence of 5–10% at the end of the first year of life [1]. Increased risk of developing the tumor is related to premature birth, low birth weight, female gender, and Caucasian race [2, 3] and also multiple gestations, increased maternal age, in vitro fertilization, pre-eclampsia and placental anomalies [4]. According to the new classification of vascular diseases, IHs are benign tumors and represent a distinct group from vascular malformations. Depending on their depth, IHs can be superficial, mixed or deep. If only the superficial dermis is affected, the color is typically bright red, whereas deeper IHs have a blue hint [5, 6]. Morphologically, IHs can be localized or segmental or exhibit an indeterminate phenotype [6, 7].

Histopathological features of IHs

From a pathogenic point of view, angiogenesis (formation of new vessels from pre-existing vessels) and vasculogenesis (de novo formation of blood vessels) participate in the process of neovascularization in hemangioma [7]. Among the cells participating in the formation of new vessels, pericytes, endothelial cells (ECs), stem/progenitor cells were studied [8, 9]. IHs have a two-stage rhythm of development, with a proliferative phase in the first year of life, more intense during the first three months, followed by the involution phase [7, 10].

During the proliferative phase, blood vessels are disorganized and composed of immature non-permeable ECs, possibly due to alpha-smooth muscle actin (α-SMA). In the involution phase of the tumor, the blood vessels mature and grow in size, but are reduced in number. The vascular tissue is replaced with fat, connective tissue, and fibroblasts [9].

As is the case with any cell, energy metabolism is a very important part of cells comprising IHs. In a normal cell, energy is obtained by mitochondrial oxidative phosphorylation under aerobic conditions. Aerobic glycolysis or the Warburg effect is another way of obtaining energy, one found in cancer cells and also in those forming hemangiomas. Investigations on glycolysis metabolism in hemangioma-derived endothelial cells (HemECs) unveiled that glucose consumption and adenosine triphosphate (ATP) production were higher in HemECs, while lactate production was lower. Also, hypoxia did not significantly alter glycolytic metabolism in these cells. Levels of glucose transporter 1 (GLUT1), human kallikrein 2 (hK2), 6-phosphofructo-2-kinase 3 (PFKFB3), lactate dehydrogenase A (LDHA) and hypoxia-inducible factor 1-alpha (HIF-1α) were higher in HemECs that in normal ECs in normoxic environment; under hypoxia, hK2, PFKFB3, pyruvate kinase M2 (PKM2), HIF-1α were higher than in normal cells. All the above-mentioned proteins are extremely important molecules for glycolysis, with a crucial role in proliferative activities, angiogenesis, and migration capacity in HemECs [9, 11, 12].
GLUT1 positive is a name tag for IHs and its inhibition causes a decrease in angiogenesis and migration of hemangioma-derived cells. Genetic silencing of PFKFB3 reduced angiogenesis. Inhibition of hK2 had a negative impact on proliferation, angiogenesis, and migration [12]. It is self-explanatory why targeting glucose metabolism may be an attractive therapeutic strategy for treating hemangiomas.

From a histological point of view (Figures 1–8), hemangiomas in their proliferative phase present lobules with a high density of capillaries-like vessels, displaying plumped ECs, a thin basal layer surrounded by a layer of pericytes [13, 14, 15]. Immunohistochemical markers used to identify hemangioma cells are GLUT1, cluster of differentiation (CD) 31, CD34, α-SMA, Ki67 [15, 16].
role on the receptors from the ECs, Propranolol inhibits cyclic adenosine monophosphate (cAMP) formation and thus decreases protein kinase A (PKA) and nitric oxide (NO) levels [18]. By the same mechanism, Propranolol reduces MAPK signaling. \textit{EPAS1} gene expression is enhanced during hypoxia periods and it encodes HIF-2α, which in turn acts upon ECs by means of vascular endothelial growth factor (VEGF), erythropoietin (EPO) and GLUT1. The action of HIF-2α however is inhibited by Propranolol’s effect on the PKA and MAPK signaling [9, 18].

Downregulation of \textit{LASP1} gene occurs during the involution phase as confirmed by reverse transcription polymerase chain reaction (RT–PCR) testing and this is the mechanism by which Propranolol inhibits MMPs formation. Independent of Propranolol treatment, there are a series of proliferation biomarkers that present a linear response. Angiopoietin 2 (\textit{ANGPT2}) gene, encoding angiopoietin 2, and secreted by the Palade bodies in the vascular endothelium, is increased under hypoxic conditions and, in the presence of VEGF, facilitates angiogenesis [16, 18].

Collagen type IV alpha 2 chain (\textit{COLA42}) gene, encoding for collagen IV, has a decreased expression during the involution phase of the hemangioma. Integrin subunit alpha 1 (\textit{ITGA1}) gene encodes for integrin αβ1 that in turn interacts with collagen IV during the proliferation stage of IH, only to be downregulated in the involution phase [18, 20].

Platelet-derived growth factor receptor-beta (\textit{PDGFRB}), ribonucleic acid (RNA) binding Fox-1 homolog 2 (\textit{RBFOX2}), matrix-remodeling-associated protein 5 (\textit{MMP5}), vasohibin 1 (\textit{VASH1}), peroxidasin (\textit{PXDN}), and \textit{COLA42} genes expression also attenuates in time, making them valuable markers for disease progression. \textit{RBFOX2} gene is a member of the Rbfox-splicing factors, and it is responsible for the alternative splicing in vascular \textit{CaV1.2} channels, which have a regulatory role for intramural pressure change because of blood flow fluctuations [21]. It has been suggested that \textit{RBFOX2} could be used as a biomarker, along with Doppler ultrasound in order to establish IH development sites based on expression levels and flow velocities [18, 22, 23].

On the other hand, ATPase Na⁺/K⁺ transporting subunit beta 1 (\textit{ATPB1}), \textit{CD9}, fibulin 1 (\textit{FLN1}), N-Myc downstream regulated 1 (\textit{NDRG1}) and secreted frizzled related protein 1 (\textit{SRFP1}) genes have an elevated expression during the involution phase of the hemangioma. \textit{ATPB1} gene encodes for a β1 subunit of a Na⁺/K⁺-ATPase, with a significant role in cell interaction and adhesion. The lowering level of \textit{ATPB1} during the initial proliferation phase suggests that IH might exhibit cancer-like mechanisms of development [18, 21].

As effective biomarkers should come from a readily attainable source, studies regarding the levels of microRNA (miRNA) and the changes that occur during different hemangioma development stages and, of course, the influence that Propranolol has on these small molecules have been made [24]. Biswas et al. identified increased urinary levels of miRNA-126 in children with a proliferative hemangioma and managed to establish a proliferation window between six and nine months of age. Afterwards, the levels of miRNA-126 in urine dropped to values encountered in healthy age-matched controls [23].
The cluster of miRNA found on chromosome 19, named C19MC is highly expressed in children with IHs and may also help differentiate them not only from healthy subjects, but also from children suffering from other types of vascular tumors. Also, circulating levels of miR-517c-3, e.g., helped identify children with either proliferative or involuting tumor and the same miRNA molecule exhibited plasma levels linked to tumor size [25]. Tissue miRNA profiling may be a tool for the differential diagnosis between IHs and non-involuting congenital hemangioma, a tumor that does not respond to Propranolol treatment [24]. Even more, the chromosome 19 miRNA cluster proved to be an effective therapy control biomarker, since its levels decreased in Propranolol-treated and involuted cases, while other miRNAs levels were unaffected [23, 25].

Cell-free miRNAs are attractive disease biomarkers and some of them even novel therapeutic targets, because of their stability in different tissue samples under a variety of preservation techniques, wide availability and specific cell uptake and release [18, 24].

Histopathological basis for differential diagnosis

Hemangiomas have superposing clinical characteristics with other soft tissue tumors with high vascular density; therefore, a thorough differential diagnostic is required. Important criteria include ultrasonography (US), clinical and histological aspects of each type of tumor [26]. Different soft tissue lumps may mimic IH and their histological portrait acts as an important discriminator.

Pyogenic granuloma

Pyogenic granuloma represents a mucocutaneous lesion commonly found on lips, gingiva, mucosa, nose, fingers, and face. Clinically, there are red or bluish papules or polyps prone to bleeding. Trauma, medications, and hormonal imbalance act as chronic irritating factors that determine an aberrant response causing the granuloma; despite the name, it has no relation to any infection. Histopathologically, there are lobules of curved capillaries and venules lined by plump ECs, with fibrous stroma and inflammatory cell infiltration. CD34-positive immunostaining is an indicator of active proliferation of the vessels [27, 28, 29].

Syringocystadenoma papilliferum

Syringocystadenoma papilliferum is a skin hamartoma, arising mainly from the apocrine gland. Clinically, it appears either as an erythematous plaque, a linear group of nodules or as a single nodule. Histopathologically, extensive papillary growth of epithelial aggregates form invaginations into the dermis. The high columnar epithelium is connected to the epidermis. Immunostaining is positive for carcinoembryonic antigen, gross cystic disease fluid protein 15 (GCDFP-15, also called BRST2), Leu-M1 antigen (CD15), lysozyme. The treatment of choice is complete surgical excision; however, carbon dioxide laser can be useful for lesions not suitable for surgery [13, 30].

Aneurysmal benign fibrous histiocytoma

Aneurysmal benign fibrous histiocytoma represents a benign dermal tumor composed of fibrohistiocytic cells. Histological studies show a mass diffusely positive for CD10 and focally for CD68, factor XIIIa, α-SMA and consistently negative for cytokeratins, S100, desmin and CD34 [31, 32].

Paronychia

Paronychia involves the soft tissue fold around the fingernail, and it is caused by a bacterial infection of the paronychial tissue. Histological studies reveal diffuse, dense, uniform plasma cell infiltrate of the upper dermis. Chronic, untreated cases may lead to osteomyelitis [29, 33, 34].

Cranial fascitis

Cranial fascitis is a benign tumor of the skull, originating in the epicranial aponeurosis. It occurs almost exclusively in children younger than six years, although it has been reported also in children younger than one year. Local trauma may be a cause. Clinically, there is a unique rapidly growing, painless scalp tumor. Histopathologically, there are fibroblasts and myofibroblasts in a myxoid or hyalinized matrix. Also, osseous metaplasia may be present [29, 35].

Metastatic neuroblastoma

Metastatic neuroblastoma is the leading malignant tumor of neonates, arising from the developing sympathetic nervous system. Clinically, “blueberry muffin baby” appearance may be the initial presentation of metastatic neuroblastoma. Histopathologically, there are neuroblasts with salt and pepper nuclei interspersed with differentiating pre-ganglion cells, neuropil, rosettes and in some cases Schwannian stroma. Significant correlations between CD44 expression and tumor prognosis were proved, CD44+ tumors having a favorable outcome [29, 36].

Extraskeletal Ewing sarcoma

Extraskeletal Ewing sarcoma is part of a family of tumors that arise in bone or soft tissue. Extraskeletal Ewing sarcoma manifests in young patients as a large, rapidly growing, and unique, superficial, or deep soft tissue mass. Histologically, it is formed by a group of high-grade small round cell tumors with prominent nuclei and indistinct cell membranes. Also, pseudo-rosettes resulting from necrosis may be present. There is a positive immunostaining for CD99, Friend leukemia integration 1 (FLI1), and vimentin [29, 37].

Plexiform fibrohistiocytic tumor

Plexiform fibrohistiocytic tumor is more common in females and typically presents in children and young adults. Clinically, there is a soft tissue nodule or indurated plaque in the subcutaneous adipose tissue. Overlying epidermis and dermis are usually normal. Histopathologically, there are plexiform or multinodular proliferation of fibrohistiocytic cells and osteoclast-like giant cells, as well as chronic inflammatory infiltrate and prominent dilated vessels. Immunostaining is positive for vimentin, CD68, α-SMA and negative for S100, cytokeratin, CD45, factor VIII, desmin [29, 38].
Ultrasonographic criteria for differential diagnosis of IH

Alongside clinical and histological evaluation of a soft tissue tumor, imaging techniques are an important source of diagnostic information required to properly classify and treat a vascular tumor. Although, magnetic resonance imaging (MRI) and computed tomography (CT)-based investigations gained a lot of attention [39, 40], US and Doppler analysis are still useful, cost-efficient, and readily available tools for any diagnostician in the quest to categorize and surveille most of the vascular malformations, including IHs and their mimics [39, 41]. During the proliferative phase, the US findings in IH are a heterogenic including IHs and their mimics [39, 41]. During the involution phase, the vessel density decreases. However, there is no pathognomonic lesion for IH, and careful analysis is required. US characteristics of the most frequent differential diagnosis for IH are summarized in Tables 1 and 2 for the benign and malignant tumors, respectively.

Table 1 – US characteristics of the frequent benign differential diagnosis

| Benign lesions | US characteristics |
|----------------|--------------------|
| Pyogenic granuloma | Ill-defined, oval; Hypoechoic, marked central and peripheral vascularization with feeders’ vessels; or Decreased peripheral vascularity; Venous and arterial flow of low resistive index. |
| Syringocystadenoma papilliferum | US findings are similar to those of a typical hemangioma. |

Wart versus eccrine poroma

| Wart | Eccrine poroma |
|------|--------------|
| Fusiform; Hypoechoic focal increase in the arterial dermal flow. | Well-defined; Hypoechoic; Avid post-contrast enhancement on MRI. |

Aneurysmal benign fibrous histiocytoma

| Aneurysmal benign fibrous histiocytoma | Well-defined, rounded; Mainly hypoechoic, posterior acoustic enhancement; Significant arterial and venous flow. |

Paronychia

| Paronychia | Diffuse, periungal thickening; Areas of increased echogenicity interposed with hypoechoic areas. |

Cranial fasciitis

| Cranial fasciitis | Small, superficial; Hypoechoic, marked internal vascularity; Venous and arterial low resistance arterial flow. |

Hemangioma

| Hemangioma | Well-defined, ovoid; Hypoechoic, high vessel density; High Doppler shift; Low flow resistance. |

MRI: Magnetic resonance imaging; US: Ultrasonography.

Table 2 – US characteristics of malignant tumors

| Malignant tumors | US characteristics |
|------------------|--------------------|
| Metastatic neuroblastoma | Blood flow consistent with localized deep hemangiomas; Peak velocity between 10–20 m/s. |
| Extraskeletal Ewing sarcoma | Hypoechoic; Increased Doppler flow; Marked internal vascularity. |

US: Ultrasonography.

Current therapeutic strategies and monitoring of IH

IH can be harmless, which is why conservative measures are recommended, but in rare cases when complications such as obstruction, bleeding, ulceration, or superinfection occur (Figures 9 and 10), therapeutic intervention is required [7, 14, 42]. Roughly for every 10 cm² increase in lesion size, there is a 4% increase in the need for treatment, and 5% increased chances for complication [42]. In the wake of the novel coronavirus disease 2019 (COVID-19) pandemic, the Hemangioma Investigator Group (HIG) released a classification of IH based on size and location useful in evaluating the probability for complications, establishing the optimum moment for initiating conservative treatment and directing the patient monitoring techniques [3] (Table 3).

Based on the factors involved in the pathogenesis of IH, over time various targeted therapies have been used: corticotherapy, interferon (IFN), sclerosing agents, β-blocker therapy and laser therapy.

Table 3 – Risk stratification depending on IH morphological characteristics, number of lesions, location [3]

| Highest | High | Medium | Low |
|---------|------|--------|-----|
| >5 cm or facial-scalp; Large or segmental lumbosacral or perineal; Multifocal IHs (≥5) and abdominal hemangiomas (US); Periocular IH with potential impact on visual axis. | Large IH on trunk/extremities Facial IH ≥2 cm (>1 cm if <3 months of age); Nasal tip or lip IH even if <1 cm; Oral; Neck or scalp IH >2 cm during growth phase; Breast; Ulcerated hemangioma. | Localizes perineal IH without ulceration; Trunk of extremity IH >2 cm especially in growth phase or if abrupt transition from normal to affected skin. | IH <2 cm on trunk of extremities in areas easily covered by clothing; IH on trunk of extremities >2 cm if gradual transition from normal to affected skin. |

IH: Infantile hemangioma; US: Ultrasonography.
**Corticosteroid therapy**

Corticosteroid (CS) therapy has been widely used in the treatment of IH. Systemic therapy using Prednisolone 2–3 mg/kg/day every morning had a 33% success rate, with only one third of lesions regressing, one-third remaining stable, and the last third showing no response [26, 39, 43]. Growth delay, skin hypopigmentation, hypertrichosis, Cushingoid appearance, behavior alteration, irritability, glaucoma, cataract are all complications associated with systemic administration of CSs [41, 43, 44]. Intralosional or topical regimes are used for small deep resistant IHs. Triamcinolone acetonide with doses from 10 to 40 mg/mL, maximum 3 mg/kg/day has important side effects such as local skin atrophy, necrosis, calcification, and depigmentation [26, 41]. Since hemangiomas have an important degree of vascularization, systemic absorption is increased even after topical treatment [26, 45].

**Imiquimod**

Imiquimod is another topical medication, which has a modulatory effect on the immune response. However, it is indicated as a third-line therapeutic agent [43, 46].

**IFN-α**

IFN-α inhibits angiogenesis, but the risk for spastic diplegia and other complications has this therapy reserved for life-threatening hemangiomas [40, 47].

**Angiotensin-converting enzyme inhibitors**

Angiotensin-converting enzyme inhibitors (ACE) have been studied as potential therapeutic agents, with a small study comparing results from Propranolol with Captopril [48]. Studies have demonstrated a likely relationship between IH development and the renin–angiotensin system (RAS) function, which prompted the investigation of ACE inhibitors, such as Captopril, as possible treatment alternatives. Overall, the β-blocker therapy showed better results, but further investigation is needed [43, 48]. Because of multiple important side effects, including anemia, peripheral neuropathy or leukopenia, Vincristine considered once a second line therapy, following CS, is now administered in the Kasabach–Merritt phenomenon (Kaposiform hemangioendothelioma and tufted angiomas) [7, 40, 42, 49].

**Bleomycin A5**

Therapy with Bleomycin A5 poses a risk for skin lesions [50, 51]. The experience of our Unit showed that Bleomycin is indicated in case of an inadequate response to Propranolol, alone or in combination with it. Reports in the literature show that Bleomycin provides better results than Triamcinolone in the treatment of IH [6, 43, 50, 52].

**β-Blocker therapy**

β-Blocker therapy has been required since 2008, when two infants treated with Propranolol for heart disease also had spectacular remission of IH [5]. Possible administration options include systemic therapy with Propranolol or Nadolol and topical applications with Timolol [53, 54]. A non-cardioselective antagonist of β1- and β2-adrenergic receptors, Propranolol appears to act by vasoconstricting high-flow blood vessels [10, 55, 56]. Nadolol has been suggested as an alternative to Propranolol because of a lower rate of complications, since Nadolol does not cross the brain barrier and does not exhibit membrane stabilizing effects [41, 45, 57]. Timolol is indicated alone [2] or in combination with laser therapy, in the case of superficial, smaller IH or in residual telangiectasias after treatment with Propranolol [41, 53, 58]. To date, Propranolol and Timolol have been maintained as first-line therapy in IH management, due to the efficacy at various locations of IH and the absence of significant adverse effects [3, 8, 13, 14, 16, 59]. Nadolol has been cited in a case report of a 10-year-old girl who, after being started on a therapy course for IH, died within seven weeks of treatment, with a postmortem concentration of Nadolol of 0.94 mg/L [60]. The infant had no bowel movements 10 days before her death. The authors of the case report suggest monitoring bowel movements in pediatric patients receiving systemic therapy with Nadolol, since this particular molecule is excreted in the feces and, in the case of discontinued bowel movements may present increased absorption [60].

Regarding Timolol, among its side effects, the literature cites transient alopecia, pulmonary fibrosis, pulmonary hypertension, hematological toxicity, hyperpigmented scars [41, 43].

Propranolol remains the main β-blocker and recent research found new ways to deliver it to the area of interest. Nanotechnology applied in the field of drug therapy helped design nanostructures that enhance drug administration efficiency. Mesoporous silica nanoparticles (MSNs) have an important role in cancer therapy and, Propranolol loading into MSNs, seem to have a cumulative effect of apoptosis of hemangioma stem cells and cell proliferation suppression [61]. The mechanism found at the base of this phenomenon is autophagy induced by synchronous release of Propranolol and nanoparticles from the MSNs and autophagosome accumulation caused by autophagy induction combined with autophagy blockade. Another mechanism consists of reactive oxygen species (ROS) generation by the Propranolol–MSNs coupling with subsequent apoptotic effects. What makes MSNs an attractive way for Propranolol delivery is the fact that this technology allows usage of lower β-blocker doses and ensures a targeted drug delivery [61].

Propranolol-loaded liposomes-in-microsphere (PLIM) is another form of prolonged delivery of Propranolol, which showed enhanced therapeutic effects when compared with free Propranolol [62].

**Laser therapy**

Laser therapy is an option for superficial, early detected hemangiomas or as an adjuvant therapy for refractory or ulcerated lesions [40, 58, 63]. Pulse dye laser (PDL) photoagulates targeted vessels while leaving the overlying skin intact [4, 43, 63]. In cases with giant hemangiomas, associated with complications, surgical treatment is the first choice for treatment [7, 64].

IH has an increased frequency among the female pediatric population, with the predominance of its localization at the skin level. The patient diagnosed with IH has the possibility of conservative treatment interventional therapy (laser therapy) or surgery. According
to the American Academy of Pediatrics (AAP), there are five indicators that prompt therapy is mandatory [7, 41]: life-threatening complications; functional impairment; ulceration; important associated structural anomalies; risk of permanent scarring or distortion of anatomic landmarks.

To summarize the AAP Guidelines, imaging of lesions is not necessary unless the diagnosis is uncertain, there are more than five cutaneous or there is a high suspicion of anatomic anomalies. Also, in case of uncertain diagnosis, US should be the first imaging diagnostic tool used. MRI should be performed when structural abnormalities are suspected [7, 41].

The European Guidelines recommend echo-cardiography whenever large hemangiomas are identified, as this is a high risk for high-output cardiac failure. For this group of patients and for those with intrahepatic hemangiomas, thyroid hormones monitoring is important as hypothyroidism may occur. MRI angiography is useful in evaluating patients with head and/or neck hemangiomas, in order to detect further arterial anomalies [4, 41, 44].

Pharmacological considerations regarding Propranolol therapy

β-Blocking therapy is by far the first choice in the treatment of IH, imposing itself by favorable clinical evolution of the tumor formation and by the lack of notable side effects, at a daily dose of 1–3 mg/kg [59]. The duration of therapy varies between 6–12 months, depending on the response. The European Guidelines suggests a lower rebound effect after a 12-months therapy course [4, 8].

It is important to note the fact that Propranolol is extensively metabolized by the liver, by means of cytochrome P450 enzymes, mainly CYP2D6. The gene polymorphism of CYP2D6 (rs1135840) was found to significantly impact the plasma amounts of Propranolol. Patients with the G/G genotype had a better response than those with the C/C genotype [65].

Highlights and pitfalls

Although no long-term effects on the central nervous system have been documented, since Propranolol is able to cross the brain barrier, other β-blockers might become a reasonable alternative to Propranolol [8, 44, 55, 57].

Second line of therapy includes oral CSs, intralesional injection of Triamcinolone, topical Timolol, depending on the morphological characteristics. Low dose CS and Propranolol could be the appropriate therapeutic plan for patients with PHACE syndrome [41]. Surgical or laser treatment is most useful for residual skin changes and may be considered to treat some IHs [40].

Considering the important changes brought by the COVID-19 pandemic, having the clinical indicators suggested by the HIG may prove useful. As such, depending on the risk group in which a patient is included, one might consider teledermatology initiation of oral or topical β-blocker or, on the contrary, house visits might be required. The standard risk group is made of patients with normal birthweight, normal cardiovascular and respiratory examination within previous four weeks, no health issues in the 24–48 hour prior to scheduled teledermatology visit, IH pattern and distribution does not match PHACE or LUMBAR syndromes, ulcerations or minimal/superficial ulceration are absent [3].

Patient and caregiver compliance are important to consider. If a patient meets the above criteria, then initiating β-blocker therapy without in-person visit may be appropriate [3].

Conclusions

The widespread occurrence and distribution of IHs can mimic other benign or malignant disorders. The main purpose of the clinician is to obtain a complete history, appropriate imaging, and sometime pathological examination in order to make an accurate diagnosis. The treatment of IH is established considering the location and extent of the tumor, number of lesions and their stage and distribution, presence of systemic involvement and/or local complications. The management of IH cases should be performed in agreement with the available guidelines. The choice between systemic or topical administration, surgery and laser therapy should be made after careful prognostic evaluation and should consider the patient compliance. Newer strategies of drug delivery may prove to be an attractive alternative to invasive measures, as more studies evaluate safety profile in direct correlation with patient’s characteristics.

Conflict of interests

The authors declare that they have no conflict of interests.

References

[1] Schupp CJ, Kleber JB, Günther P, Holland-Cunz S. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatr Dermatol, 2011, 28(6):640–644. https://doi.org/10.1111/j.1525-1470.2011. 01569.x PMID: 21995836
[2] Cheraghliou S, Lim Y, Choea K. Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention. F1000Res, 2019, 8:F1000 Faculty Rev-590. https://doi.org/10.12688/f1000research.16160.1 PMID: 31069062 PMCID: PMC6492225
[3] Frieden IJ, Püttgen KB, Drolet BA, Garzon MC, Chamlin SL, Pope E, Mancini AJ, Lauren CT, Mathes EF, Siegel DH, Gupta D, Haggstrom AN, Tollesfon MM, Baselaeg E, Morel KD, Shah SD, Holland KE, Adams DM, Horii KA, Newell BD, Powell JM, McCuaig CC, Nopper AJ, Metry DW, Magunissen S, Hemangioma Investigator Group. Management of infantile hemangiomas during the COVID pandemic. Pediatr Dermatol, 2020, 37(3):412–418. https://doi.org/10.1111/pde.14196 PMID: 32298480 PMCID: PMC7262142
[4] Hoeger PH, Harper JI, Baselaeg E, Bonnet D, Boon LM, Ciofi Degli Atti M, El Hachem M, Oranje AP, Rubin AT, Weibel L, Léauté-Labrèze C. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr, 2015, 174(7):855–865. https://doi.org/10.1007/s00431-015-2570-0 PMID: 26021855
[5] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Borsale F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med, 2008, 358(24):2649–2651. https://doi.org/10.1056/NEJMoa0708819 PMID: 18550886
[6] Pandey V, Tiwari P, Sharma SP, Kumar R, Singh OP. Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol. Int J Oral Maxillofac Surg, 2018, 47(7):908–912. https://doi.org/10.1016/j.iomj.2018.03.024 PMID: 29665992
[7] Callahan AB, Yoon MK. Infantile hemangiomas: a review. Saudi J Ophthalmol, 2012, 26(3):283–291. https://doi.org/10.1016/j.sjopt.2012.05.004 PMID: 23961007 PMCID: PMC3724953
[8] Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, Chun RH, Garzon MC, Holland KE, Liberman L,
MacLeellan-Tobert S, Mancini AJ, Metry D, Putten KB, Seefeldt M, Sidbury R, Ward KM, Blei F, Basgela E, Cassidy L, Darrow DH, Joachim S, Kwon EKM, Martin K, Perkins J, Siegel DH, Boucek RJ, Frieden IJ. Initiation and use of propranolol for infantile hemangiomas: report of a consensus conference. Pediatrics. 2013, 131(1):128–140. https://doi.org/10.1542/peds.2012-1691 PMID: 23266923 PMCID: PMC359954

[9] Chen J, Wu D, Dong Z, Chen A, Liu S. The expression and role of glycogen-associated molecules in infantile hemangioma. Life Sci. 2020, 259:118215. https://doi.org/10.1016/j.lfs.2020.118215 PMID: 32768579

[10] Awadein A, Fakhry MA. Evaluation of intral sneal propranolol for pericul ar capillary hemangioma. Clin Ophthalmol. 2011, 5:1135–1140. https://doi.org/10.2147/OPTH.S22909 PMID: 21887095 PMCID: PMC3162293

[11] Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, Senema GL. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell, 2011, 145(7):732–744. https://doi.org/10.1016/j.cell.2011.03.054 PMID: 21620138 PMCID: PMC3130564

[12] Draoui N, de Zeeuw P, Carmeliet P. Angiogenesis revisited. Circ Res. 2011, 108(1):e1–e10. https://doi.org/10.1161/CIRCRESAHA.110.227723 PMID: 21363336

[13] Na, K-ATPase beta1-subunit. J Mol Cell Cardiol, 2009, 47(4):552–560. https://doi.org/10.1016/j.yjmcc.2009.07.018 PMID: 19683723 PMCID: PMC2749246

[14] Khanna S, Roy S, Pearson G, Arya AD, Wilson DI, Baralle D, Raponi M. RBFOX2 protein profiling in infantile hemangiomas. Eplasty, 2019, 19:e13. PMID: 31068993 PMCID: PMC6482871

[15] Strub GM, Kirsh AL, Whipple ME, Kuo WP, Keller RB, Kapur RP, Majesky MW, Perkins JA. Endothelial and circulating C19MC microRNAs are a hallmark of infantile hemangiomas. JCI Insight, 2016, 1:e88856. https://doi.org/10.1172/jci.insight.88856 PMID: 27660822 PMCID: PMC5029419

[16] Sethuraman G, Yenamandra VK, Gupta V. Management of infantile hemangiomas: current trends. J Cutan Aesthet Surg, 2014, 7(2):75–85. https://doi.org/10.4103/0974-2077.138324 PMID: 25136206 PMCID: PMC4134656

[17] Can muscular fibers in infantile hemangiomas: subclinical reversion to a fetal phenotype. Pediatr Radiol, 2011, 41(1):17–23. https://doi.org/10.1007/s00247-010-1823-z PMID: 21096037

[18] Bisswas A, Pan X, Meyer M, Kanna S, Roy S, Pearson G, Kirschner R, Witman P, Sen CK, Gordillo GM. Urinary excretion of microRNA-126 is a biomarker for hemangioma proliferation. Plast Reconstr Surg, 2017, 139(6):1277–1284e. https://doi.org/10.1097/PRS.000000000000349 PMID: 28538656 PMCID: PMC5963954

[19] Schulz BE, Spock CR, Tom LK, Kong Y, Canadas KT, Kim S, Waner M, O T, Antaya R, Narayan D. MicroRNA microarray profiling in infantile hemangiomas. Eplasty, 2019, 19:e13. PMID: 31068993 PMCID: PMC6482871

[20] Strub GM, Kirsh AL, Whipple ME, Kuo WP, Keller RB, Kapur RP, Majesky MW, Perkins JA. Endothelial and circulating C19MC microRNAs are a hallmark of infantile hemangiomas. JCI Insight, 2016, 1:e88856. https://doi.org/10.1172/jci.insight.88856 PMID: 27660822 PMCID: PMC5029419

[21] Kirschner R, Witman P, Faith EF, Sen CK, Gordillo GM. Cardiac contractility in mice with heart-specific ablation of Na+,K-ATPase beta1-subunit. J Mol Cell Cardiol, 2009, 47(4):552–560. https://doi.org/10.1016/j.yjmcc.2009.07.018 PMID: 19683723 PMCID: PMC2749246

[22] Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Baselga E, Cassidy L, Niday AE, Cojocaru E, Rotaru ST, Butnariu LI, Cojocaru E. MicroRNA microarray profiling in infantile hemangiomas. Eplasty, 2019, 19:e13. PMID: 31068993 PMCID: PMC6482871

[23] Bisswas A, Pan X, Meyer M, Kanna S, Roy S, Pearson G, Kirschner R, Witman P, Sen CK, Gordillo GM. Urinary excretion of microRNA-126 is a biomarker for hemangioma proliferation. Plast Reconstr Surg, 2017, 139(6):1277–1284e. https://doi.org/10.1097/PRS.000000000000349 PMID: 28538656 PMCID: PMC5963954

[24] Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, Annam A, Baker CN, Frommelt PC, Hodak A,
Pate BM, Pelletier JL, Sandrock D, Weinberg ST, Whelan MA; Subcommittee on the Management of Infantile Hemangiomas. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics, 2019, 143(1):e20183475. https://doi.org/10.1542/peds.2018-3475 PMID: 30584062

Cheng CE, Friedlander SF, Infantile hemangiomas, complications: and treatments. Semin Cutan Med Surg, 2016, 35(3): 108–116. https://doi.org/10.1016/j.scr.2016.05.050 PMID: 27607318

Satterfield KR, Chambers CB. Current treatment and management of infantile hemangiomas. Surv Ophthalmol, 2010, 64(5):608–618. https://doi.org/10.1016/j.survophthal.2010.02.005 PMID: 20772366

Greenberger S, Bischoff J. Infantile hemangio – mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med, 2011, 1(1):a006460. https://doi.org/10.1101/cshperspect.a006460 PMID: 22229118 PMCID: PMC3234458

Kim KH, Choi TH, Choi Y, Park YW, Hong KY, Kim DY, Cho YS, Lee H, Cheon JE, Park JB, Park KD, Kang HJ, Shin HY, Jeong JH. Comparison of efficacy and safety between propranolol and steroid for infantile hemangiomia: a randomized clinical trial. JAMA Dermatol, 2017, 153(6):529–536. https://doi.org/10.1001/jamadermatol.2017.0250 PMID: 28423174 PMCID: PMC5817616

Senchak AJ, Dann M, Cable B, Bessinger G. Successful treatment of cutaneous hemangioma of infancy with topical imiquimod 5%: a report of 3 cases. Ear Nose Throat J, 2010, 89(3):E21–E25. PMID: 20229466

Wu HW, Wang X, Zhang L, Zhao HG, Wang XA, Su LX, Fan XD, Zheng JW. Interferon-alpha therapy for refractory kaposiform hemangioendothelioma: a single-center experience. Sci Rep, 2016, 6:36281. https://doi.org/10.1038/srep36281 PMID: 27796340 PMCID: PMC5087085

Zaher H, Rasheed H, El-Komy MM, Hegazy RA, Gawdat H, Abdel Halim DM, Abdel Hay RM, Hegazy RA, Mohy AM. Propranolol versus captopril in the treatment of infantile hemangiomia (IH): a randomized controlled trial. J Am Acad Dermatol, 2016, 74(3):499–505. https://doi.org/10.1016/j.jaad.2015.09.061 PMID: 26865718

Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, Bernabeu-Wittel J, Ramirez-Villar GL. Long-term outcome of vincristine-aspirin–ticlopidine (VAT) therapy for vascular tumors associated with Kasabach–Merrit phenomenon. Pediatr Blood Cancer, 2013, 60(9):1478–1481. https://doi.org/10.1002/pbc.24543 PMID: 23609996

Luo QF, Zhao FY. The effects of Bleomycin A5 on infantile facial hemangioma. Head Face Med, 2011, 7:11 https://doi.org/10.1186/1746-160X-7-11 PMID: 21736714 PMCID: PMC3148961

Muir T, Kirsten M, Fournie P, Dippenaar N, Ionescu GO. Intraleisonal bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int, 2004, 20(4):405–411. https://doi.org/10.1007/s00383-005-1036-6 PMID: 14740248

Plenacar C, Graham R, Geldenhuys S, Hudson DA. Intraleisonal bleomycin for the treatment of hemangiomas. Plast Reconstr Surg, 2006, 117(1):22–29. https://doi.org/10.1097/01.PR.S.0000194861.60805.b0 PMID: 16402471

Chambers CB, Katowitz WR, Katowitz JA, Binenbaum G. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. Ophthalmic Plast Reconstr Surg, 2012, 28(2):103–106. https://doi.org/10.1097/IOP.0b013e31823836ff PMID: 22410658

Corresponding Authors
Elena Cojocaru, Associate Professor, MD, PhD, Department of Morphofunctional Sciences I – Pathology, Grigore T. Popa University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania; Phone +40745-367 144, e-mail: ellacojocaru@yahoo.com
Laura Mihaela Trandafir, Associate Professor, MD, PhD, Department of Mother and Child Medicine – Pediatrics, Grigore T. Popa University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania; Phone +40721-471 041, e-mail: trandafirlaura@yahoo.com

Received: October 18, 2020 Accepted: March 23, 2021

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics